Objective: Prostate cancer (PCa) is a complex disease characterized by diverse cellular ecosystems within the tumor microenvironment (TME) and high tumor heterogeneity, which challenges clinically stratified management and reinforces the need for novel strategies to fight against castration-resistant PCa (CRPC).
Methods: We performed single-cell RNA sequencing (scRNA-seq) on 10 untreated primary PCa tissues and integrated public scRNA-seq resources from three normal prostate tissues, two untreated primary PCa tissues, and six CRPC tumors to portray a comprehensive cellular and molecular interaction atlas of PCa. We further integrated the single-cell and bulk transcriptomes of PCa to establish a molecular classification system.
The production of high-energy-density liquid fuels through the photoconversion of CO offers a highly efficient method for storing sustainable solar energy for future use. BiTiO (BTO) nanorods loaded with Cu-Pd nanoalloys were designed for the highly selective photoreduction of CO to ethyl alcohol, using HO as the proton source. A tandem synergistic catalysis mechanism was proposed for this CO photoconversion process.
View Article and Find Full Text PDFPurpose: Immune checkpoint plus tyrosine kinase inhibition (IO + TKI) has emerged as the first-line therapy in metastatic renal cell carcinoma (RCC), but no biomarker can predict its efficacy. Thymidine kinase 1 (TK1) is closely associated with immune evasion in tumors.
Methods: Metastatic RCC patients treated by IO + TKI were enrolled from two cohorts (ZS-MRCC, n = 45; Javelin-101, n = 726).
Quorum sensing(QS) is a crucial aspect of Anammox(anaerobic ammonium oxidation) technology operation. Given the difficulty of accumulating Anammox bacteria, the favorable characteristics of sludge are vital for optimizing the stable operation of Anammox systems. Therefore, it is essential to study the interaction between QS and the physical properties of sludge in the Anammox process.
View Article and Find Full Text PDFThe self-homodyne detection (SHD) is a promising solution to achieve low-cost and low-power-consumption fiber-optic communications. In this work, we propose and demonstrate a high-capacity spatial-division multiplexing (SDM) system with SHD technology by employing single-mode multi-core fibers (SM-MCFs), where the fan-in/fan-out (FIFO) 3D photonic devices are designed and fabricated based on the femtosecond laser direct writing technique, enabling high-efficiency coupling between single-mode fibers (SMFs) and SM-MCFs. The FIFO 3D photonic devices, serving as the SDM (de)multiplexer, facilitate superior performance of low insertion loss and low inter-channel crosstalk.
View Article and Find Full Text PDFStable inhibition of nitrite-oxidizing bacteria (NOB) is a significant challenge in achieving partial nitrification (PN) and partial nitrification-anaerobic ammonia oxidation (PNA). Growing evidence suggested that NOB can develop resistance to suppression over time, leading to the re-enrichment of NOB within reactors. To address these issues, this study aimed to achieve stable PN by regulating SRT to selectively washout NOB during the lag phase of activity recovery following FA/FNA exposure.
View Article and Find Full Text PDFThe high-rate contact stabilization (HiCS) process, a variant of high-rate activated sludge, has gained attention for its superior energy recovery and enhanced biosorption capabilities. The need for efficient energy recovery in HiCS necessitates a high settling efficiency to minimize resource loss due to endogenous sludge consumption. However, the low sludge retention time (SRT) required for HiCS can significantly affect sludge floc stability and flocculation performance, warranting a deeper analysis of the factors influencing these characteristics.
View Article and Find Full Text PDFA novel double-shelled CuS/CdInS photocatalyst was rationally designed using CdInS sheets grown upon the exterior of hollow CuS nanocubes. The unique hierarchical hollow structure of CuS/CdInS provides numerous active sites and reduces carrier diffusion length. Surface sulfur vacancies mitigate the detachment of the intermediate, which is favorable for a multi-electron reaction path such as that in the production of CH.
View Article and Find Full Text PDFBackground: Integrated immune checkpoint inhibitors (ICIs) plus tyrosine kinase inhibitors (TKIs) are now the recommended first-line therapy to manage renal cell carcinoma (mRCC). Proteasome 26S subunit non-ATPase 2 (PSMD2) overexpression in tumors has been correlated with tumor progression. Currently, mRCC lacks an established biomarker for the combination of ICI+TKI.
View Article and Find Full Text PDFClinical guidelines have recently advised combination therapy involving immunotherapy (IO) and tyrosine kinase inhibitors (TKI) as the first-line therapy approach for advanced renal cell carcinoma (RCC). Nevertheless, there is currently no available biomarker that can effectively distinguish the progression-free survival (PFS). RNA-sequencing and immunohistochemistry were conducted on our cohort of metastatic RCC patients, namely ZS-MRCC, who received combination therapy consisting of IO and TKI.
View Article and Find Full Text PDFAcoustic communication plays important roles in the survival and reproduction of anurans. The perception and discrimination of conspecific sound signals of anurans were always affected by masking background noise. Previous studies suggested that some frogs evolved the high-frequency hearing to minimize the low-frequency noise.
View Article and Find Full Text PDFBackground: In renal cell carcinoma (RCC), no clinically available biomarker has been utilized for checkpoint inhibitor immunotherapy (IO) + tyrosine kinase inhibitor (TKI) combinations. Galectin-1 overexpression is found in tumors, with potential immune-regulating roles.
Methods: RNA-sequencing was performed in two cohorts of RCC treated with IO/TKI combination therapy (ZS-MRCC, JAVELIN-101).
Background: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) therapy is the first-line recommendation for advanced renal cell carcinoma (RCC), but no biomarker has been approved for it. Annexin A2 (ANXA2) can induce immune escape in tumors.
Methods: Two independent cohorts of advanced RCC treated by IO + TKI were utilized for survival analysis (ZS-MRCC, n = 45; Javelin-101, n = 726).
Background: Checkpoint inhibitor immunotherapy plus tyrosine kinase inhibitor (IO/TKI) have been recently recommended as standard first-line therapy for advanced renal cell carcinoma, while no clinical-available biomarker has been applied. This study aimed to investigate the associations between RUNX3 pathway signature and IO/TKI benefits in renal cell carcinoma (RCC).
Methods: Two IO/TKI cohorts (ZS-MRCC, JAVELIN-101) and one high-risk localized RCC cohort (ZS-HRRCC) were included.
Intravesical prostatic protrusion (IPP) is common in prostate-related diseases, whose clinical significance in radical prostatectomy was unknown. 791 patients underwent robot-assisted or open radical prostatectomy at our institution were enrolled. The transabdominal ultrasound examination of prostate and IPP was carried out preoperatively, by which IPP was classified as no (0-0.
View Article and Find Full Text PDFSelf-homodyne detection (SHD) is a promising approach to realize high-capacity short-reach optical transmission systems with low cost and low power consumption. We experimentally demonstrate single-carrier net 800-Gb/s SHD transmission with low-cost ∼MHz linewidth distributed feedback (DFB) laser over 2 km, 10 km, 25 km, and 40 km single-mode fiber (SMF) using three different quadrature amplitude modulation (QAM) formats, including 80-Gbaud dual-polarization (DP) 64QAM, 100-Gbaud DP-32QAM, and 120-Gbaud DP-16QAM. Among them, net 800-Gb/s DP-64QAM SHD transmission over 25 km SMF using an uncooled DFB laser with a linewidth of 2.
View Article and Find Full Text PDFBackground: Immunotherapy plus tyrosine kinase inhibitor (IO-TKI) has become the first-line management for metastatic renal cell carcinoma (RCC), despite the absence of biomarkers. Recently, pyrroline-5-carboxylate reductase 1 (PYCR1) and proline metabolism have been reported regulatory roles in the anti-tumor response.
Methods: There were three cohorts enrolled: two from our institution (ZS-MRCC and ZS-HRRCC) and one from a clinical trial (JAVELIN-101).
Checkpoint inhibitor immunotherapy plus tyrosine kinase inhibitor (IO/TKI) has become the first-line treatment for metastatic renal cell carcinoma (RCC), despite the lack of biomarkers. Cyclin-dependent kinase 6 (CDK6) has shown a regulatory role in antitumour response. The study enrolled two cohorts of metastatic RCC treated by IO/TKI (Zhongshan Hospital [ZS]-MRCC, n = 45; JAVELIN-101, n = 726) and two cohorts of localized RCC (ZS-HRRCC, n = 40; TCGA-KIRC, n = 530).
View Article and Find Full Text PDFBackground: Basal cell carcinoma (BCC) is a prevalent cutaneous cancer with an increasing incidence. Nucleolar and spindle associated protein 1 (NUSAP1) is a cell proliferation-related protein that participates in the development of various cancers. However, its role and mechanism in BCC remain elusive.
View Article and Find Full Text PDFBackground: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) emerged as standard first-line therapy for advanced renal cell carcinoma (RCC). The heme Oxygenase 1 (HMOX1) pathway is involved in tumor development and treatment resistance, which may affect the efficacy of TKI + IO.
Methods: Two cohorts from our center (ZS-MRCC, ZS-HRRCC), one cohort from clinical trial (JAVELIN Renal 101) and the Cancer Genome Atlas (TCGA-KIRC) were enrolled.
Purpose: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) has become the first-line treatment for advanced renal cell carcinoma, despite the lack of prognostic biomarkers. Cyclin-dependent kinase 5 (CDK5) affects the tumor microenvironment, which may influence the efficacy of TKI+IO.
Materials And Methods: Two cohorts from our center (Zhongshan Metastatic Renal Cell Carcinoma [ZS-MRCC] cohort, Zhongshan High-risk Localized Renal Cell Carcinoma [ZS-HRRCC] cohort) and one cohort from a clinical trial (JAVELIN-101) were enrolled.